Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 ISCOMATRIX vaccine in resected malignant melanoma
NCT00199901Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Sep 2005
- Primary completion
- Dec 2008
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of NY-ESO-1 ISCOMATRIX vaccine in melanoma, sponsored by Ludwig Cancer Research. Started Sep 2005; status: completed.
02
Drugs
NY-ESO-1 ISCOMATRIX vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00199901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00199901.